Key Highlights

  • Humana (NYSE:HUM) sank 12.98% on November 18, 2026 and became the S&P 500's weakest performer, while UnitedHealth's 10.21% decline was the biggest weight on a Dow that gave up 561.25 points.
  • Under the proposal, CMS would apply audit error rates to whole Medicare Advantage contracts, looking back to 2018 payments, and it estimates about USD 90.2 billion could be recovered from 2027 through 2036.
  • agilon health was off roughly 21%, Elevance Health 7.63% lower and Centene 7.03% lower, and the health care sector as a whole gave up 2.20%.
  • The Federal Register is expected to carry the proposal on November 19, with comments closing January 19, 2027, which means the final rule may still change.

1. Humana (NYSE:HUM)

Humana (NYSE:HUM) carries the most exposure of the five, since government health plans generate most of its sales. Diversified competitors with large commercial, pharmacy or services divisions have other profit pools to lean on, while Humana has fewer. The stock lost 12.98% on November 18 after a 3.88% decline the day before, a two-session drop of roughly 16% that made it the S&P 500's largest faller. The rule targets risk adjustment data validation audits, which examine whether the diagnoses that raise a plan's payments are documented in medical records. At present, repayments are linked to the records actually reviewed. Under the proposal, the error rate from a sample would be carried across the entire contract, a change that can magnify the sum owed, and the look-back would extend to 2018. Humana has consistently opposed extrapolation and was one of the parties that challenged the 2023 rule, which a federal court in Texas set aside on procedural grounds. The timing is what stands out now. The proposal comes as insurers contend with heavier medical spending and tighter Medicare reimbursement, leaving them little room to absorb repayments. Shareholders want Humana to quantify its exposure and state whether 2027 plan pricing or benefits will shift. Until that happens, the stock will likely respond to every development out of Washington.

2. UnitedHealth (NYSE:UNH)

UnitedHealth (NYSE:UNH) runs the country's largest Medicare Advantage operation, so it ranks second here even though its Business is more diversified. The shares fell 10.21% on November 18 and had dropped 5.42% on November 17, a combined decline near 15%. Because the Dow is price weighted, UnitedHealth explains a large part of the index's 561.25 point drop down to 50,198.17, whereas the Nasdaq Composite gained 0.42%. The exposure has two sides. If the rule is finalised, the company might have to hand back past payments, and it could also see future margins shrink if plans must change how they document patient conditions. Investors are concerned that repayments could weigh on Earnings for years, even though the measure is still only a proposal. Dividend holders will want to see whether the company can keep its dividend and buyback commitments on track. The stock has fallen to some of its lowest prices in years, a dramatic change for a name once regarded as defensive. Leveraged products designed to deliver two times UnitedHealth's daily move dropped roughly 20%, intensifying the sell-off. Insurers will probably contend that extrapolation is unfair without an adjustment for coding errors in traditional Medicare, an argument raised in earlier cases, and a milder final version would probably draw buyers back fast.

3. agilon health (NYSE:AGL)

agilon health (NYSE:AGL) slid roughly 21% during the November 18 session, trading near USD 115, and it ranks third because its model depends on Medicare Advantage Economics despite not being an insurer. The company partners with primary care doctors to care for Medicare Advantage members under value based contracts, sharing savings and losses on medical costs. No company-specific announcement accounting for the drop was located, so the link to the proposal is an inference from timing and business exposure. Reduced payments to insurers could over time limit the funds available to provider partners like agilon. The drop occurred despite a reasonable recent report: third quarter adjusted earnings of USD 1.97 a share surpassed an expected loss, Revenue hit USD 1.51 billion, and management pushed its 2026 adjusted EBITDA forecast up into a USD 145 million to USD 155 million band. A share price this elevated for a business of this scale reflects a 1-for-25 reverse split that took hold on March 30, 2026. On November 18 an analyst maintained a hold rating and a USD 112 target, close to where the stock was trading. The key issues are how agilon's insurer agreements split any recovered payments and whether provider rates come under pressure. Until that is clearer, the stock is likely to move alongside the insurers.

4. Elevance Health (NYSE:ELV)

Elevance Health (NYSE:ELV) dropped 7.63% on November 18, less than Humana or UnitedHealth, thanks to a sizeable commercial and Medicaid book that adds balance. It ranks fourth because its Medicare Advantage membership has expanded in recent years, raising its sensitivity to the proposal. The size of each insurer's decline roughly matched its reliance on Medicare Advantage relative to other lines, and the wide sell-off points to investors treating the proposal as an industry-wide issue, not one confined to a couple of names. Plenty of investors had previously stepped away from managed care amid climbing healthcare utilization, meaning some of the threat could already be reflected in prices. Still, a loss of this size across two sessions indicates the proposal was not fully expected. Borrowing costs add pressure, as the 10-year Treasury Yield hovers around 5.07% and Fed minutes indicating almost every official expects more hikes, defensive sectors such as health care face competition from higher bond yields among income investors. Insurers have yet to estimate how much of the USD 90.2 billion they could owe, and those figures will shape valuations. Company remarks and industry commentary over the coming weeks are the next signals for the shares.

5. Centene (NYSE:CNC)

Centene (NYSE:CNC) lost 7.03% on November 18 and sits fifth because its Medicare book is dwarfed by Medicaid and marketplace enrolment. Such a split leaves it less directly exposed to the audit proposal than Humana or UnitedHealth, although the decline shows investors were not sparing any major insurer. CVS Health, which owns Aetna, dropped 5.20%, a fall cushioned by its pharmacy and benefit management units, while Molina Healthcare was about 4.97% lower by afternoon. Health care sank 2.20% that day, trailing just energy on the sector scoreboard across the 11 S&P 500 groups. Near term, the open question for Centene is how investors price a company whose core programs rely on government funding while Washington pushes for tougher payment controls. CMS is trying to reinstate clauses that a Texas federal court struck from a 2023 rule, which makes fresh litigation plausible given that record. Outcomes could run from a shorter look-back window to a Carve-Out for coding errors in traditional Medicare. More than half of eligible beneficiaries are enrolled in Medicare Advantage, and legislators from both parties have constituents who rely on these plans, a Factor that could temper the final text. Until exposure estimates surface, Centene will probably trade with the broader managed care group instead of on its own results.

Where Things Stand

Among the five Medicare Advantage stocks, Humana carries the most exposure to the CMS audit rule because it leans most heavily on government plans. UnitedHealth operates the largest Medicare Advantage book, agilon health's fortunes track its provider partners, and Elevance Health and Centene report more evenly spread businesses. Comments are due January 19, 2027.